KOPN earnings call summary

Prepared Highlights

• Q2 2025 total revenues were $8.5 million, down from $12.3 million in Q2 2024, driven by government budget uncertainty and reduced customer confidence (CFO).
• Product revenues were $7.5 million (Q2 2025) vs. $11.1 million (Q2 2024); funded R&D revenues decreased by $0.9 million to $1.2 million due to completion of the CR3 medical headset (CFO).
• Cost of product revenues was $7.1 million or 94% of net product revenues (Q2 2025), compared to $8.7 million or 79% in Q2 2024; lower sales insufficient to absorb fixed costs (CFO).
• R&D expenses were $1.9 million in Q2 2025, up $0.1 million from prior year; customer-funded R&D down $0.2 million, internal R&D up $0.3 million due to display transition to Europe and production line automation (CFO).
• SG&A expenses were $7.9 million in Q2 2025 vs. $7.3 million in Q2 2024; decrease primarily due to a $2.8 million reduction in legal fees (CFO).
• Net loss for Q2 2025 was $5.2 million or $0.03 per share, compared to a net loss of $5.9 million or $0.05 per share in Q2 2024 (CFO).
• Net cash used in operating activities was $7.6 million for the first half of 2025 (CFO).
• Announced a $15 million strategic investment from Theon International; preferred shares have a fixed conversion price of $3.00 and a forced conversion price of $4.50 if stock trades above that level for 10 days in a 30-day window (CEO).
• Sales with Theon expected to commence in Q4 2025; Theon reported revenues of over $381 million last year with a >50% CAGR over the past 6 years (CEO).
• Pipeline includes the $22 billion U.S. Army SBMC (formerly IVAS) program; several programs have congressional budget demands through 2030 and IDIQ contracts (CEO).
• Official guidance: No specific revenue or earnings guidance ranges provided for next quarter or full year.
• Mgmt quotes:
  • “It's been quite a busy and transformational time at Kopin and we believe some of our best and most exciting opportunities still lay ahead of us.” (CEO)
  • “We did not meet our expectations. This was largely the result of government budget uncertainty and subsequent customer confidence that was reduced which created a sales vacuum in the second quarter.” (CEO)
  • “We are very pleased to report that the order book is recovering, and many of those orders will be fulfilled in the third quarter.” (CEO)
  • “We believe we're at an exciting inflection point for the company.” (CEO)
  • “I believe the best is yet to come.” (CEO)

Prepared Metrics

Q&A Batch (1-2 of 2)

Q1 — Jaeson Allen Min Schmidt

• Topic: Theon投资机会的规模、独占性及Q2订单情况
• Key points:
  • 与Theon的合作收入预计从Q4开始，来源包括内部采购（OLED、LCD、MicroLED）、应用解决方案（DayVAS和DarkWAVE）以及研发资金。
  • 合作非排他性，但将提升Dalgety Bay和Reston工厂的产能利用率，从而改善成本结构。
  • Q2 book-to-bill为正，但低于预期，主要因季度内转单和部分研发订单未如预期到位；仍有约2000万美元的受资助研发订单预计在2025年下半年确认。
• Mgmt stance: bullish — 明确指引Q4开始贡献收入，强调利用率提升将传导至利润，并确认大部分预期订单已收到。

Q2 — Glenn George Mattson

• Topic: 制造自动化进展及Theon合作的前任供应商
• Key points:
  • Q2已引入光学检测自动化，预计下半年节省100-150万美元运营费用；第二阶段自动化将在2025年底前完成，预计2026年再减少约100万美元OpEx。
  • 对于Theon原供应商身份未予明确，合作重点在于开发OLED/MicroLED/LCD及DayVAS/DarkWAVE，并在欧洲本地生产。
  • 公司之前已将OLED产线移至欧洲，现可直接从欧洲向Theon（希腊）出货，无需经过美国。
• Mgmt stance: bullish — 自动化节省数字明确，Theon合作被视为“变革性”，并强化了欧洲供应链优势。